SPOTLIGHT -
Closing Remarks on Treating Patients with HR+ Breast Cancer
Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.
Read More
Treatment after Progression on CDK4/6 Inhibitors
A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.
The Role of Surgery in Breast Cancer
Experts in oncology consider when surgery is appropriate for patients with breast cancer.
Overview of Treatment Options for Patients with Breast Cancer
Breast cancer experts provide a comprehensive overview of treatment options and clinical trials in breast cancer.
Patient Profile 2: A 62-Year-Old Woman with Metastatic HR+ Breast Cancer
Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, analyze a patient case of a 62-year-old woman with metastatic HR+ breast cancer.
Clinical Insights on the Use of Adjuvant Therapy Plus Abemaciclib in HR+ Breast Cancer
Detailed clinical insights on the use of adjuvant therapy plus abemaciclib in patients with high-risk, early stage HR+ breast cancer.
Abemaciclib Plus Adjuvant Endocrine Therapy in Breast Cancer
Using the monarchE trial as a benchmark, experts in oncology discuss the use of abemaciclib with adjuvant endocrine therapy in patients with high-risk, early stage HR+ breast cancer.
Patient Profile 1: A 56-Year-Old Woman with Early HR+ Breast Cancer
Expert oncologists offer their initial impressions of a profile of a 56-year-old woman with early stage, HR+ breast cancer.
HR+ Breast Cancer: Incidence, Prognosis, and Risk Stratification
Sara Tolaney, MD, MPH, and Massimo Cristofanilli, MD, discuss factors that affect risk stratification of patients with HR+, HER2- breast cancer.
Updated Results of APHINITY at 8.4 Years Median Follow Up
Dr Sara M Tolaney reviews data from the APHINITY trial regarding the pertuzumab plus trastuzumab and chemotherapy treatment regimen for patients with HER2+ breast cancer.
Ongoing Clinical Trials With ADC Therapy in HR+ Metastatic Breast Cancer
Breast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.
HR+ Metastatic Breast Cancer: What is the Role of Antibody-Drug Conjugates?
Centering discussion on antibody-drug conjugates in HR+ metastatic breast cancer, panelists consider the selection and use of these agents in practice.
HER2-Low Metastatic Breast Cancer and Use of Trastuzumab Deruxtecan
Centering their discussion on the HER2 low setting of HR+ metastatic breast cancer, medical oncologists review data behind trastuzumab deruxtecan therapy.
Treatment for HR+ Metastatic Breast Cancer After Progression on CDK4/6 Inhibitors
Shared insight on appropriate treatment options for patients with HR+ metastatic breast cancer following progression on CDK4/6 inhibitors.
HR+ Metastatic Breast Cancer: Continuing CDK4/6 Inhibition Beyond Progression
Expert panelists consider when it is appropriate to continue the use of CDK4/6 inhibitors beyond progression in HR+ metastatic breast cancer.
Interpreting Data With CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer
In the context of recent clinical trials, experts share their perspective on the selection and use of CKD4/6 inhibitor therapy in patients with HR+ metastatic breast cancer.
Brief Review of SERM Therapy Data in HR+ Metastatic Breast Cancer
Closing out their review of endocrine therapy in HR+ metastatic breast cancer, panelists consider clinical trial data with selective estrogen receptor modulators [SERMs].
What is the Role of Oral SERD Therapy in HR+ Metastatic Breast Cancer?
Comprehensive insight to the development and use of selective estrogen receptor degraders [SERDs] in HR+ metastatic breast cancer treatment.
HR+ Metastatic Breast Cancer: Overview of the Current Treatment Landscape
Opening their discussion on the HR+ metastatic breast cancer treatment landscape, expert oncologists share a broad overview of treatment modalities in this setting.
Future Directions in the Management of HER2+ Breast Cancer
Before closing out the discussion on the management of HER2+ breast cancer, experts share their excitement on future treatment strategies.
Patient Profile 5: Strategies for Managing Elevated Liver Function Tests in Patients on the HER2CLIMB Regimen
Experts consider how best to manage adverse events associated with the HER2CLIMB regimen in the setting of HER2+ metastatic breast cancer.
Patient Profile 4: Managing AEs in Patients Receiving Treatment for HER2+ BC
A brief discussion on optimally managing adverse events while treating patients with HER2+ breast cancer.
Patient Profile 4: Strategies for Managing ILD in Patients Receiving Trastuzumab Deruxtecan
Sara Tolaney, MD, provides practical advice for managing interstitial lung disease in patients with metastatic HER2+ breast cancer.
Patient Profile 3: Treatment Sequencing in a Patient with metastatic HER2+ Breast Cancer
Shared insight on factors for selecting therapy in a patient with HER2+ metastatic breast cancer progressing through multiple lines of therapy.
Patient Profile 3: 43-Year-Old Woman With Metastatic Breast Cancer Progressing Through Multiple Lines of Therapy
Expert oncologist Rena Callahan, MD, shares a real-world clinical scenario of a 43-year-old woman with metastatic breast cancer who progressed through multiple lines of therapy.
Patient Profile 2: Treatment Sequencing in a Patient with Progressive Brain Metastases
Expert perspectives on use of trastuzumab deruxtecan in patients with HER2+ breast cancer who develop brain metastases.
Patient Profile 2: Clinical Utility of the HER2CLIMB Regimen for HER2+ mBC
Centering discussion on a real-world patient profile, subject matter experts discuss use of the HER2CLIMB regimen in HER2+ breast cancer.
Patient Profile 2: How Should T-DM1 Be Sequenced in HER2+ mBC?
Considerations for the role of trastuzumab emtansine in HER2+ breast cancer with the advent of newer HER2-targeted therapies.
Patient Profile 2: Strategies for Managing Brain Metastases in HER2+ Metastatic Breast Cancer
Shared insight on strategies for managing brain metastases in patients with HER2+ breast cancer.
Patient Profile 2: 26-Year-Old Woman With Triple Positive Breast Cancer
Shanu Modi, MD, presents the clinical scenario of a 26-year-old woman with triple positive breast cancer.
Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma
TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy
Liso-Cel Leads to Rapid Responses, High Undetectable MRD Rates in Relapsed/Refractory CLL/SLL
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC